Analysts Anticipate Viveve Medical Inc (VIVE) Will Announce Earnings of -$0.30 Per Share
Wall Street brokerages expect Viveve Medical Inc (NASDAQ:VIVE) to report ($0.30) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Viveve Medical’s earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.36). Viveve Medical posted earnings per share of ($0.49) in the same quarter last year, which suggests a positive year-over-year growth rate of 38.8%. The firm is expected to report its next earnings results after the market closes on Thursday, May 9th.
According to Zacks, analysts expect that Viveve Medical will report full-year earnings of ($0.94) per share for the current financial year, with EPS estimates ranging from ($1.48) to ($0.69). For the next year, analysts expect that the firm will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.99) to ($0.34). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last posted its earnings results on Thursday, March 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Viveve Medical had a negative net margin of 266.96% and a negative return on equity of 669.39%. The company had revenue of $4.47 million during the quarter, compared to analyst estimates of $4.33 million.
A number of hedge funds and other institutional investors have recently modified their holdings of VIVE. Nantahala Capital Management LLC grew its stake in Viveve Medical by 66.7% during the 4th quarter. Nantahala Capital Management LLC now owns 6,581,465 shares of the company’s stock valued at $6,911,000 after purchasing an additional 2,633,333 shares in the last quarter. RTW Investments LP grew its stake in Viveve Medical by 42.4% during the 4th quarter. RTW Investments LP now owns 4,480,565 shares of the company’s stock valued at $4,705,000 after purchasing an additional 1,333,333 shares in the last quarter. Meitav Dash Investments Ltd. grew its stake in Viveve Medical by 30.1% during the 1st quarter. Meitav Dash Investments Ltd. now owns 988,573 shares of the company’s stock valued at $955,000 after purchasing an additional 228,517 shares in the last quarter. J. Goldman & Co LP grew its stake in Viveve Medical by 55.8% during the 1st quarter. J. Goldman & Co LP now owns 537,600 shares of the company’s stock valued at $505,000 after purchasing an additional 192,584 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in Viveve Medical during the 1st quarter valued at approximately $36,000. Hedge funds and other institutional investors own 61.01% of the company’s stock.
Shares of VIVE stock traded up $0.02 during trading hours on Friday, reaching $0.47. The company had a trading volume of 4,030 shares, compared to its average volume of 690,484. The company has a debt-to-equity ratio of 6.21, a quick ratio of 3.51 and a current ratio of 3.89. Viveve Medical has a twelve month low of $0.42 and a twelve month high of $4.34. The firm has a market cap of $21.70 million, a P/E ratio of -0.28 and a beta of 0.42.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.
Recommended Story: What is a blue-chip stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.